Osteoporosis Drugs Market Size Is Anticipated To Reach $16.3 Billion By 2025

The global osteoporosis drugs market is expected to reach USD 16.3 billion by 2025, according to a new study by Grand View Research, Inc. An upsurge rise in the unhealthy lifestyle adoption has resulted in aggravation and increase in the prevalence of osteoporosis which is presumed to propel the osteoporosis drugs market during the forecast period.

In addition, growing number of patent expiries is fueling the high clinical urgency to use generic versions of the established drugs, which is presumed to fuel generic osteoporosis drugs market during the forecast period. The aforementioned factors cumulatively are slated to present the with high potential growth opportunities over the coming years.

Furthermore, rising number of initiatives to increase the awareness levels pertaining to osteoporosis care amongst the patients as well as the physicians is expected to widen the osteoporosis market growth potential during the forecast period. For instance, National Osteoporosis Foundation (NOF), a healthcare organization responsible for National Bone Health Alliance and Fracture Liaison Service (FLS) care coordination programs that focuses on elevating awareness levels as well as provides training to healthcare professionals

Full Research Report On Osteoporosis Drugs Market Visit Here: https://www.grandviewresearch.com/industry-analysis/osteoporosis-drug-market

Further key findings from the study suggest:

• Branded drugs held the dominant share of the product segment in 2015. The dominant share can be attributed to extensive utilization of bisphosphates, rank ligand inhibitors for the treatment of osteoporosis, possessing high efficacy
• Generics are expected to witness at a lucrative CAGR owing to consistent patent expiries over the coming years as well as high clinical urgency for inexpensive medication in the emerging economies
• In 2015, North America accounted for the largest share in the global osteoporosis drugs market owing to the presence of established companies extensively involved in the commercialization of branded therapeutics
• Asia Pacific is anticipated to grow at an exponential CAGR as a consequence of favorable government initiatives promoting information pertaining to osteoporosis care
• The key participants are employing sustainability strategies promoting the adoption of osteoporosis therapeutics to gain competitive advantage. For instance, Actavis Inc. announced to acquire Warner Chilcott PLC in order to widen their product portfolio

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/osteoporosis-drug-market/request/rs1

Grand View Research has segmented the osteoporosis drugs market on the basis of product and region:

Global Osteoporosis Product Outlook (Revenue, USD Million, 2014 – 2025)

• Branded
• Bisphosphonates
• Parathyroid Hormone Therapy
• Calcitonin
• Selective Estrogen Inhibitors Modulator(SERM)
• Rank Ligand Inhibitors
• Others
• Generics

Osteoporosis Drugs Regional Outlook (Revenue, USD Billion, 2014 – 2025)

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• Asia Pacific
• Japan
• China
• India
• Latin America
• Mexico
• Brazil
• MEA
• South Africa

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Therapeutic Respiratory Devices Market Size Is Estimated To Reach $18.0 Billion By 2025

The global therapeutic respiratory devices market is anticipated to reach USD 18.0 billion by 2025, according to a new report by Grand View Research, Inc. Growing geriatric population base, rising prevalence of respiratory diseases, and rapid technological advancements are the key factors that are driving the market growth.

The therapeutic respiratory devices market growth is anticipated to increase due to rapid technological advancements in the market.Now-a-days, the respiratory monitoring devices utilize software applications for the collection and analysis of data from ventilators equipped across the health system. The tools in the software application allow improvised patient monitoring by the measurement of parameters such as process and clinical variation in the ventilator therapy.

Furthermore, waveform capnography is a useful technical advancement in monitoring the carbon dioxide levels. The launch of new products such as automated and stand-alone pressure controller for mechanical ventilators boost the growth of therapeutic respiratory devices market. These pressure controllers enable reduction in the risk of tracheal injuries and Ventilator Associated Pneumonia (VAP). For instance, in May 2015, Fischer and Paykel launched its new product AIRVO Nasal High Flow System, which provides comfort and stability for patients. It has soft contoured cheek pads and prongs, uninterrupted power supply transport, and tube technology with two way spiral design. The company also offers humidifier with integrated flow generator, which delivers high flows of air mixture to spontaneously breathing patient. Such factors are bolstering the growth of the market.

Full Research Report On Therapeutic Respiratory Devices Market Visit Here: https://www.grandviewresearch.com/industry-analysis/therapeutic-respiratory-devices-market

Further Key Findings From the Study Suggest:

• Positive airway pressure devices accounted for the largest share in 2016 owing to technological innovations resulting in increased portability and shelf life.
• HEPA filter technology accounted for the largest share in 2016, due to the prevalence of respiratory diseases & their transmission coupled with technological advancements in this segment.
• Humidifiers is anticipated to be the fastest growing segment in the forecast period owing to the rising demand for humidifiers in hospitals, schools, home, & healthcare entities, and increased prevalence of airborne infections such as tuberculosis.
• North America therapeutic respiratory devices market is the largest market and is expected to maintain its position over the forecast period owing to the presence of large geriatric population base and rising prevalence of chronic respiratory diseases.
• Major players of the market include, Carefusion Corporation, GE Heathcare, AirSep Corporation, Philips Healthcare, Smiths Medical and Covidien PLC.

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/therapeutic-respiratory-devices-market/request/rs1

Grand View Research has segmented the global therapeutic respiratory devices market on the basis of product, technology, filters, and region:

Therapeutic Respiratory Devices Product Type Outlook (Revenue, USD Million, 2014 - 2025)

• Nebulizers
• Compressor-based nebulizers
• Piston based hand held nebulizer
• Ultrasonic Nebulizer
• Humidifiers
• Heated humidifiers
• Passover humidifiers
• Integrated humidifiers
• Built-In humidifiers
• Stand-alone humidifiers
• Oxygen Concentrators
• Fixed oxygen concentrators
• Portable oxygen concentrators
• Positive Airway Pressure Devices
• Continuous positive airway pressure devices
• Auto-titrating positive airway pressure devices
• Bi-level positive airway pressure devices
• Ventilators
• Adult ventilators
• Neonatal ventilators
• Capnographs
• Gas Analyzers

Therapeutic Respiratory Devices Technology Outlook (Revenue, USD Million, 2014 - 2025)

• Electrostatic Filtration
• HEPA filter technology
• Hollow fiber filtration
• Microsphere separation

Therapeutic Respiratory Devices Filters Outlook (Revenue, USD Million, 2014 - 2025)

• Nebulizer filters
• Inlet filter
• Replacement filter
• Cabinet filter
• Humidifier filters
• Wick filters
• Permanent cleanable filters
• Mineral absorption pads
• Demineralization cartridges
• Positive airway pressure devices filter
• Ultra fine foam inlet filters
• Polyester non-woven fiber filters
• Acrylic & Polypropylene fiber filters
• Oxygen concentrator filters
• HEPA filter
• Cabinet filter
• Pre-Inlet filter
• Inlet filter
• Micro disk filter
• Felt intake filter
• Bacterial filter
• Hollow-membrane filter
• Ventilator filters
• Mechanical filters

• HEPA Filters
• ULPA Filters
• Activated carbon filters
• Electrostatic filters
• Tribocharged filters
• Fibrillated filters

Therapeutic Respiratory Devices Regional Outlook (Revenue, USD Million, 2014 - 2025)

• North America
• U.S.
• Canada
• Europe
• Spain
• Germany
• France
• Italy
• Switzerland
• Asia Pacific
• India
• China
• Japan
• Latin America
• Brazil
• Mexico
• MEA
• South Africa

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Next Generation Cancer Diagnostics Market Size Is Predicted To Reach $11.04 Billion By 2024

The global next generation cancer diagnostics market is anticipated to reach USD 11.04 billion by 2024, according to a new report by Grand View Research, Inc. Key drivers for this vertical include rising advancement in genomics and proteomics-based research coupled with increasing prevalence of oncology disorders.

Rise in number of oncological research projects to elucidate tumorigenesis and the underlying mechanisms, consequently raising the demand for serial sampling, diagnosis, and therapeutic manipulation, is a growth rendering driver of this market.

Full Research Report On Next Generation Cancer Diagnostics Market Visit Here: https://www.grandviewresearch.com/industry-analysis/next-generation-cancer-diagnostics-market

Further Key Findings from the Study Suggest:

• The qPCR & multiplexing segment captured the largest market share in 2015 owing to the presence of a wide product portfolio serving numerous applications in oncology R&D
• Next generation sequencing services and solutions for oncology applications are anticipated to be the fastest growing segment
• Oncology diagnostics in biomarker discovery is expected witness growth as it subsequently facilitates drug designing and identification of novel targets against tumors
• On the basis of cancer type, this vertical is segmented into lung, breast, colorectal, cervical, and other forms of cancer
• Research projects to establish the therapeutic index of anticancer cytotoxic drugs are one of the key factors responsible for expected growth
• North America dominated the market with respect to revenue generation in 2014 due to concerted efforts directed toward the development of next generation sequencing technology and companion diagnostics in personalized medicine
• Some of the key players contributing significantly to the next generation cancer diagnostics market are Novartis AG; Cepheid; Hoffman La Roche Ltd.; PerkinElmer, Inc.; Sysmex Corporation; Abbott; Thermo Fisher Scientific, Inc.; Koninklijke Philips N.V.; Agilent Technologies; Illumina, Inc.; Genomic Health, Inc.; Qiagen; Janssen Global Services, LLC; Hologic, Inc.; Myriad Genetics, Inc.; Almac Group; Opko Health, Inc.; and GE Healthcare.

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/next-generation-cancer-diagnostics-market/request/rs1

Grand View Research has segmented the next generation cancer diagnostics market on the basis of technology, application, cancer type, function, and region:

Technology Outlook (Revenue, USD Million, 2013 - 2024)

• Next Generation Sequencing
• qPCR & Multiplexing
• Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
• Protein Microarrays
• DNA Microarrays

Application Outlook (Revenue, USD Million, 2013 - 2024)

• Biomarker Development
• CTC Analysis
• Proteomic Analysis
• Epigenetic Analysis
• Genetic Analysis

Cancer Type Outlook (Revenue, USD Million, 2013 - 2024)

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Others

Function Outlook (Revenue, USD Million, 2013 - 2024)

• Therapeutic Monitoring
• Companion Diagnostics
• Prognostics
• Cancer Screening
• Risk Analysis

Regional Outlook (Revenue, USD Million, 2013 - 2024)

• North America
• U.S
• Canada
• Europe
• Germany
• France
• Asia Pacific
• Japan
• China
• Latin America
• Brazil
• Middle East & Africa
• South Africa

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Breast Cancer Drugs Market Size Is Estimated To Reach $38.4 Billion By 2025

The global breast cancer drug market size is expected to reach USD 38.4 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 10.7% during the forecast period. Early detection, increase in awareness, and incidence of breast cancer are some of the key trends stoking market growth.

Global breast cancer drugs market is expected to grow lucratively as many players focus majorly on R&D of innovative treatments. They engage in extensive research to develop novel drugs for the treatment of the disease to gain a higher market share. There exists a growing pressure and need for novel therapies and treatment due to rapidly accelerating prevalence of diseases. The strong pipeline is expected to provide new and effective treatment options and improved outcomes than existing therapies.

With advancements in drug delivery systems, various target specific therapies have been customized and designed as a carrier to infuse the therapeutic agent to the target site. Carriers for inducing target therapy include modified anticancer agent’s specific to molecular-recognition-element, anticancer peptides, and nanoparticle-based anticancer drugs. For instance, HER2/neu protein is usually given in combination with other anti-cancer drugs in targeted therapy.

F. Hoffman-La Roche Ltd leads the breast cancer drugs market with Herceptin, Perjeta, and Kadcyla. However, rapid advancements in biosimilars with a goal to offer cost effective alternatives to patients is anticipated to put pressure on this space. For instance, in December 2017, the Food and Drug Administration (FDA) approved the first biosimilar of trastuzumab for HER2+ breast cancer.

Full Research Report On Breast Cancer Drugs Market Visit Here: https://www.grandviewresearch.com/industry-analysis/breast-cancer-drugs-market

Further key findings from the report suggest:

• HER2 inhibitors is expected to be the most preferred drug class segment over the forecast period, owing to their high specificity as they are subclass of target therapy
• CDK 4/6 inhibitor is expected to be the fastest growing segment over the forecast period. There are currently more than 45 CDK 4/6 inhibitor drug candidates in pipeline
• North America held the largest market share in 2017 owing to the factors such as the presence of key manufacturers in the country, high awareness and adoption, and well-established healthcare infrastructure among others
• Europe was estimated to be the second largest regional segment in 2017 due to increasing incidence of breast cancer and growing R&D investments
• Asia Pacific is anticipated to witness healthy growth over the next decade due to increasing incidence of breast cancer, rise in awareness about early diagnosis in emerging countries such as China and India.
• Companies such as F. Hoffmann-La Roche Ltd; Pfizer Inc.; AstraZeneca; Novartis AG; Astellas Pharma Inc.; and Eli Lilly and Company dominated the breast cancer drugs market
• The market is lucrative and competitive in nature as manufacturers engage in new product development to increase their product penetration. Moreover, they are entering into collaborations and partnerships to enhance their product portfolio.

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/breast-cancer-drugs-market/request/rs1

Grand View Research has segmented the global breast cancer drugs market on the basis of type and region:

Breast Cancer Drug Type Outlook (Revenue, USD Million, 2014 - 2025)

• HER2 Inhibitors
• Mitotic Inhibitors
• Anti-metabolites
• Aromatase Inhibitors
• CDK 4/6 Inhibitors
• Hormonal Receptor

Breast Cancer Drugs Regional Outlook (Revenue, USD Million, 2014 - 2025)

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• Asia Pacific
• China
• India
• Japan
• Central & South America
• Brazil
• Mexico
• Middle East & Africa
• South Africa

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com